How is patient care for multiple myeloma advancing?

Expert Review of Hematology
Sonja Genadieva StavricAlessandra Larocca

Abstract

Treatment of multiple myeloma has undergone profound changes in the past years thanks to the increased understanding of the biology of the disease and the new treatment options. New drugs and effective approaches are currently available for the treatment of multiple myeloma, including immunomodulatory agents, proteasome inhibitors and autologous stem cell transplantation. Areas covered: We have described the recent updated criteria to start treatment in multiple myeloma and summarized clinical data from major studies including most recent agents. Particularly, results with pomalidomide, carfilzomib, ixazomib, monoclonal antibodies such as elotuzumab, daratumumab, and checkpoint inhibitors have been reported. Both transplant and non-transplant settings have been covered. Expert commentary: Despite the successful improvement in overall survival and time to relapse, multiple myeloma still remains incurable. Therefore, there is still an unmet need for new treatment strategies with novel mechanisms of action, like monoclonal antibodies, novel immunomodulators, and novel proteasome inhibitors. Implementation of these novel drugs in rationally designed therapies with a good balance of efficacy and safety should be carefully considered...Continue Reading

References

May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 22, 2007·The New England Journal of Medicine·Robert A KyleS Vincent Rajkumar
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
Apr 3, 2010·Blood Reviews·David Dingli, S Vincent Rajkumar
Mar 16, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruno PaivaJesus F San Miguel
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson
Apr 28, 2011·Nature Reviews. Clinical Oncology·S Vincent Rajkumar
Apr 14, 2012·Blood·Jonathan J KeatsP Leif Bergsagel
Apr 11, 2013·Drugs·Shelley Elkinson, Paul L McCormack
Aug 2, 2013·The New England Journal of Medicine·María-Victoria MateosJesús-F San Miguel
Jan 17, 2014·Nature Communications·Niccolo BolliNikhil C Munshi
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Dec 3, 2014·The Lancet Oncology·S Vincent RajkumarJesus F San Miguel
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Güllü GörgünKenneth C Anderson
May 21, 2015·American Society of Clinical Oncology Educational Book·María-Victoria Mateos, Jesús-F San Miguel
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Jul 29, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosJ San-Miguel
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Sep 2, 2015·Blood·Alessandra Larocca, Antonio Palumbo
Jan 6, 2016·Drugs·Kate McKeage

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.